Safety and Efficacy Study of BrainPort® Balance Device in Peripheral Vestibular Dysfunction.

June 27, 2012 updated by: Wicab

A Controlled Clinical Study to Evaluate the Safety and Efficacy of the BrainPort® Balance Device When Used to Improve Balance in Subjects With Peripheral Vestibular Dysfunction

The purpose of this study is to assess the safety and efficacy of the BrainPort balance device in improving balance and gait as measured by clinically accepted standardized balance assessments in subjects with peripheral vestibular dysfunction.

Study Overview

Detailed Description

Peripheral vestibular dysfunction can be caused by inner ear disorders, drug toxicity, neuritis, or a number of other causes. In the absence of a fully functional vestibular system, the brain often requires retraining to correctly utilize visual and proprioceptive cues to maintain postural stability. People with vestibular dysfunction experience multiple problems with posture control and movement, including an unsteady gait and various balance-related difficulties. These effects make it very difficult to walk in the dark or on uneven surfaces without risk of falling. They are typically referred for conventional vestibular therapy. Many patients improve with therapeutic intervention. Some patients reach a plateau and do not return to their previous level of function. The BrainPort balance device transmits head position information via electrotactile stimulation of the tongue. With training, patients learn to use the positional information to correct their balance.

Participants meeting the study criteria will be randomized to the perceived stimulation or subliminal stimulation group. All participants will be given baseline assessments of postural stability, balance, and subjective well being according to standardized tests. After completing the baseline assessments, each participant will be trained in the clinic using a standard training protocol with the BrainPort balance device. Each participant will participate in 6 clinical training sessions, over a period of 3 consecutive days. Upon completion of the clinic training sessions, participants will continue with a 7½ week period of home use. During this period, the participant will train with the device for 20 minutes 2 times per day and the clinicians will contact the participants weekly. At the end of the home training period (8 weeks from the beginning of the study), all participants will again undergo the tests given at baseline.

Following the data analysis, subjects that have completed the 8 week study and were originally assigned to the group with inferior results will be given the opportunity to use the device that showed superior results in the data analysis.

Study Type

Interventional

Enrollment (Actual)

147

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • Los Angeles, California, United States, 92840
        • England Physical Therapy
    • Colorado
      • Centennial, Colorado, United States, 80111
        • South Valley Physical Therapy, PC
    • Florida
      • Jupiter, Florida, United States, 33458
        • Sensory Therapeutics, Inc.
      • N. Miami Beach, Florida, United States, 33160
        • NBC Rehabilitation
    • Georgia
      • Atlanta, Georgia, United States, 30342
        • Atlanta Ear Clinic
      • Augusta, Georgia, United States, 30912
        • Medical College of Georgia
    • Idaho
      • Boise, Idaho, United States, 83702
        • Elks Hearing & Balance Center
    • Kansas
      • Kansas City, Kansas, United States, 66160
        • Kansas University Medical Center
    • Massachusetts
      • Burlington, Massachusetts, United States, 01805
        • Lahey Clinic
    • Missouri
      • Springfield, Missouri, United States, 65897
        • Missouri State University
    • New York
      • New York, New York, United States, 10010
        • New York Eye and Ear Infirmary
      • Rochester, New York, United States, 14642
        • University of Rochester Medical Center
    • Texas
      • Houston, Texas, United States, 77024
        • Houston ENT Clinic
    • Virginia
      • Norfolk, Virginia, United States, 23507
        • Eastern Virginia Medical School
    • Washington
      • Seattle, Washington, United States, 98195
        • University of Washington School of Medicine
      • Seattle, Washington, United States, 98109
        • Pacific Balance and Rehabilitation Clinic
    • Wisconsin
      • Milwaukee, Wisconsin, United States, 53215
        • Aurora St. Luke's Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Confirmed diagnosis of peripheral vestibular dysfunction by the following (within 12 months of study enrollment):

    1. Bilateral Vestibular Hypofunction (BVH)-Sinusoidal rotary chair results at least 2 SD below normal across the frequency range of 0.01 to 0.32 Hz, and at least 60 deg/s peak velocity.
    2. Unilateral Vestibular Hypofunction (UVH)-Bithermal caloric test results of > 25% unilateral weakness.
  2. Minimum post 3 months diagnosis with residual balance problems.
  3. Previously treated with conventional physical therapy, and discharged and/or reached a plateau.
  4. Functional Ability:

    1. Able to ambulate independently or with an assistive device for 20 feet.
    2. Ability to stand independently for 2 minutes with no or minimal upper extremity support.
    3. Dynamic Gait Index ≤ 19/24.
  5. Able to read and sign the informed consent form.
  6. Fluent in English.
  7. Willing and able to complete all testing, training, and follow-up evaluations required by the study protocol.

Exclusion Criteria:

  1. Current oral health problems as determined by health questionnaire and an examination of the oral cavity.
  2. Any medical condition that would interfere with performance on the assessments.
  3. Known neuropathies of the tongue.
  4. Prior exposure to BrainPort balance device.
  5. History of seizures or epilepsy.
  6. If female, pregnant. Subject must deny pregnancy and agree to use appropriate birth control to prevent pregnancy for the duration of the study.
  7. People with implanted electrical medical devices (i.e. pacemaker, deep brain stimulator).
  8. People currently taking any vestibular suppressant medication (i.e. barbiturates, benzodiazepines, betahistines or cortisone).
  9. People with a previous diagnosis of a central nervous system lesion (e.g. stroke or brain injury).
  10. Current diagnosis of any of the following:

    1. Bilateral areflexia (no response to ice water caloric testing bilaterally)
    2. Progressive neurological disease (such as Multiple Sclerosis)
    3. Cervicogenic dizziness
    4. Pre-syncope/syncope episodes
    5. Orthostatic hypotension
    6. Mood Disorders (such as Major Depression and Bipolar Disorder)
    7. Anxiety disorders
    8. Hydrops / Ménière's
  11. Principal Investigator, in his or her medical judgment, does not believe the subject is a good candidate for the trial.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Perceived stimulation
When subjects assigned to the perceived stimulation group increase the intensity of the stimulus, they will feel a tingling sensation on the tongue. The tingling will move on the tongue in relation to where the head/body moves.
Subjects are randomly assigned to one of two groups, the perceived stimulation group or the subliminal stimulation group. Some of these devices provide a stimulus that you can feel. Others provide a stimulus that is below conscious awareness. We are conducting this study to determine if one type of stimulation is more effective than the other.
Other Names:
  • BrainPort Balance Device
Experimental: Subliminal stimulation
When subjects assigned to the subliminal stimulation group increase the intensity of the stimulus, the device provides a stimulus that is below their conscious awareness, so they will not be able to perceive it. The stimulus will move on the tongue in relation to where the head/body moves.
Subjects are randomly assigned to one of two groups, the perceived stimulation group or the subliminal stimulation group. Some of these devices provide a stimulus that you can feel. Others provide a stimulus that is below conscious awareness. We are conducting this study to determine if one type of stimulation is more effective than the other.
Other Names:
  • BrainPort Balance Device

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
To assess the efficacy of the BrainPort balance device in improving balance and gait as measured by the Dynamic Gait Index (DGI) in subjects with documented peripheral vestibular dysfunction
Time Frame: Baseline and 8 weeks (end of study)
Baseline and 8 weeks (end of study)

Secondary Outcome Measures

Outcome Measure
Time Frame
To assess the safety of electrical stimulation of the tongue during the use of the BrainPort balance device in subjects with documented peripheral vestibular dysfunction.
Time Frame: Baseline and ongoing for the duration of the study (8 weeks).
Baseline and ongoing for the duration of the study (8 weeks).
To assess improvement in the Activities-specific Balance Confidence scale (ABC).
Time Frame: Baseline and 8 weeks (end of study)
Baseline and 8 weeks (end of study)
To assess improvement in the Dizziness Handicap Inventory (DHI).
Time Frame: Baseline and 8 weeks (end of study)
Baseline and 8 weeks (end of study)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: James O. Phillips, PhD, University of Washington

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2008

Primary Completion (Actual)

March 1, 2010

Study Completion (Actual)

March 1, 2010

Study Registration Dates

First Submitted

October 6, 2008

First Submitted That Met QC Criteria

October 6, 2008

First Posted (Estimate)

October 8, 2008

Study Record Updates

Last Update Posted (Estimate)

June 28, 2012

Last Update Submitted That Met QC Criteria

June 27, 2012

Last Verified

June 1, 2012

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Vestibular Diseases

Clinical Trials on Training with the BrainPort balance device

Subscribe